“A comprehensive diagnostic offering workflow increases the rate of actionable results of the 23- and 35-gene expression profile tests for use as ancillary diagnostic tools for difficult-to-diagnose melanocytic lesions” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s79. doi:10.25251/skin.5.supp.79.